Can Pilots Take Wegovy? What Aviators Need to Know Before Starting

Picture this: your AME has cleared you medically, but you haven't mentioned the semaglutide prescription you're considering

That gap is where problems begin. Pilots are required, under their medical certificate conditions, to disclose newly prescribed medicines to their Aeromedical Examiner or the relevant aviation medical authority before flying on them. Wegovy is no exception. Failing to disclose is not a grey area, it puts your licence at risk regardless of whether the medicine itself causes any problem.

The UK Civil Aviation Authority sets fitness standards under EASA-derived regulations. These cover not just medical conditions but the medicines used to treat them. Whether a specific drug is acceptable for a given licence class depends on factors including its pharmacological effects, how long a pilot has been stable on it, and whether the underlying condition being treated is itself disqualifying. Weight, for instance, is not automatically a disqualifying condition, but it can contribute to conditions that are, such as obstructive sleep apnoea or type 2 diabetes, both of which have their own aeromedical frameworks.

The honest starting point, then, is a conversation with your AME before you apply for a prescription, not after. A prescriber at a regulated pharmacy assesses your suitability for Wegovy as a medicine; your AME assesses your suitability to fly while taking it. Both assessments matter, and neither replaces the other. Learn more about what a Wegovy prescription involves by reading how Wegovy works as a licensed weight-management treatment.

The side effects that concern aviation medicine most

Semaglutide's side-effect profile is well-documented in clinical trial data and summarised on the NHS medicines page for semaglutide. For most people the effects are gastrointestinal (nausea, loose stools, indigestion) and they cluster around the start of treatment and after each dose increase, typically settling within a week or two.

For pilots, that cluster is the crux of the aeromedical concern. Nausea in a cockpit is not merely uncomfortable; it is a distraction and, in single-crew operations, a genuine safety factor. Dizziness and fatigue, also reported, have obvious implications for situational awareness. These are exactly the reasons aviation authorities require a ground-based stabilisation period before a pilot can return to flying duties on any new medicine with a significant side-effect profile.

The STEP 1 trial, published in the New England Journal of Medicine, reported that gastrointestinal events were the most commonly recorded adverse effects with semaglutide 2.4mg, occurring in the majority of participants at some point during treatment. For a private pilot these effects may be manageable with lifestyle adjustments; for a commercial pilot flying under an instrument rating, the calculus the CAA applies is considerably stricter. If you are curious about the specific injection process and what starting treatment actually looks like day to day, the guide on how Wegovy injections are taken covers the practical detail.

Private, PPL and commercial licences: why the threshold differs

Aeromedical standards are tiered. A Class 1 medical (required for airline transport pilot licences (ATPL) and commercial pilot licences (CPL)) applies the strictest criteria, because the pilot may be the sole safeguard for fare-paying passengers. Class 2 (for private pilots holding a PPL) and LAPL medicals operate under less stringent standards, though they are not permissive about cockpit incapacitation risk.

In practice, the CAA has historically required Class 1 licence holders to demonstrate a defined period of stable treatment on any new medicine, on the ground, before returning to line flying. The length of that period depends on the drug class. GLP-1 receptor agonists are a relatively recent arrival in this context, and published CAA-specific guidance for semaglutide may be updated as operational experience accumulates. Checking the current CAA aeromedical documentation directly (and doing so through your AME rather than a general internet search) gives you the authoritative answer for your specific licence type and flying role.

Men who fly and are wondering whether Wegovy is appropriate for them more broadly may find the overview of Wegovy for men a useful read alongside any aeromedical discussion. The semaglutide clinical background page also covers the licensed evidence base in full. One cost-related consideration worth noting: private treatment pricing (context on what a prescription service includes) is laid out on the weight-loss treatments page.

The practical steps if you want to explore this further

Step one is your AME, before any prescription request. Bring your current medical certificate, list your existing medicines, and ask directly whether semaglutide is currently acceptable under CAA aeromedical standards for your licence class. Ask specifically about the required ground-based period, the reporting obligations, and how a dose increase would be handled.

Step two, if your AME gives the go-ahead, is a clinical consultation with a prescribing service. At nume, every consultation is read by a GPhC-registered Independent Prescriber (not automated triage) who reviews your health history in full. That process is where Wegovy's clinical suitability for you as an individual is assessed. The aeromedical dimension is something you bring into that conversation, too; a prescriber who knows you are a licence holder can factor it into their assessment and correspondence.

Wegovy is also now available in a higher 7.2mg dose, approved by the MHRA on 14 April 2026. Whether that dose is relevant to you depends on how your treatment progresses; the Wegovy 1mg dosing page explains how the titration schedule works at different points. For questions about what the prescription document itself looks like, the Wegovy patient information leaflet page is a reliable reference. And if you want to know more about how Wegovy may interact with cardiovascular risk factors, that page covers the evidence in detail.

If you have a question that isn't answered here, the contact page connects you with the clinical team directly. When you are ready to take the next step, speak to our prescribers through a free consultation, it costs nothing and commits you to nothing.